Diaminohydroxypropanetetraacetic acid clinical trials
How each study uses diaminohydroxypropanetetraacetic acid is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the diaminohydroxypropanetetraacetic acid studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 4
Abbott Medical Devices (1) · Boston Scientific Corporation (1) · Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland (1) · Vincent ROULE (1) · Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o. (1) · HonorHealth Research Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses diaminohydroxypropanetetraacetic acid is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCIRecruitingPhase 3Vincent ROULENCT07164859Written as short dual antiplatelet therapy (DAPT) durationHow we know
- Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)RecruitingPhase 3Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.NCT07195149Written as DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)How we know
- SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet TherapyTerminatedPhase 2HonorHealth Research InstituteNCT03606642Written as Dual Antiplatelet (DAPT) TherapyHow we know
- XIENCE 28 USA StudyCompletedNot applicableAbbott Medical DevicesNCT03815175Written as DAPT (aspirin and/or P2Y12 receptor inhibitor)How we know
- EVOLVE Short DAPT StudyCompletedPhase 4Boston Scientific CorporationNCT02605447Written as 3 months of dual antiplatelet therapy (DAPT)How we know
- DES Versus BiOSS LIM - POLBOS II StudyCompletedPhase 4Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, PolandNCT02198300Written as Dual antipletlet therapy (DAPT)How we know
As the comparator · 6 — what is tested is compared with diaminohydroxypropanetetraacetic acid
- Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)RecruitingNot applicableGan LijunNCT07587099Written as Dual antiplatelet therapy (DAPT)How we know
- Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)RecruitingPhase 4J.P.S HenriquesNCT06916520Written as Dual Antiplatelet (DAPT) TherapyHow we know
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)RecruitingNot applicableFondazione Ricerca e Innovazione Cardiovascolare ETSNCT06535568Written as Dual antiplatelet therapy (DAPT)How we know
- Rivaroxaban for Slow Coronary Flow After PCI in STEMINot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07195812Written as Dual Antiplatelet (DAPT) TherapyHow we know
- Personalization of Long-Term Antiplatelet Therapy - RAPID EXTENDTerminatedPhase 4Ottawa Heart Institute Research CorporationNCT03729401Written as Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice dailyHow we know
- ACCEL-LOADING-ACS StudyCompletedPhase 4Gyeongsang National University HospitalNCT01354808Written as Dual Anti-Platelet Therapy (DAPT)How we know
What changed recently
From the registry's own updates since Oct 21, 2026.
Started recruiting1
- Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCINov 3, 2026NCT07164859
Codes
What other systems call diaminohydroxypropanetetraacetic acid · ClinicalTrials.gg INT015785
- RxNorm 1659205One source FDA
- Wikidata Q27271662diaminohydroxypropanetetraacetic acidOne source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 1659205 | — | One source FDA |
| Wikidata | Q27271662 | diaminohydroxypropanetetraacetic acid | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.